Azemiglitazone is under clinical development by Cirius Therapeutics and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData, Phase II drugs for Metabolic Dysfunction-Associated Steatohepatitis (MASH) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Azemiglitazone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Azemiglitazone overview
MSDC-0602 (MSDC-0602K) is under development for the treatment of non-alcoholic steatohepatitis (NASH). It is formulated as a capsule and administered orally. The drug candidate is an NCE (new chemical entity) insulin sensitizer that modulates mTOT (mitochondrial target of thiazolidinediones). It was also under development for the treatment of type II diabetes and polycystic kidney disease.
Cirius Therapeutics overview
Cirius Therapeutics (Cirius) is a clinical-stage pharmaceutical company that primarily focuses on the development of innovative therapies for disease caused by insulin resistance, including Type 2 Diabetes, the metabolic consequences of obesity, and metabolic dysfunction-associated steatotic liver disease and metabolic associated steatohepatitis (MASLD/MASH). Its lead product candidate azemiglitazone MSDC-0602K is a small molecule being developed as a once-daily oral therapy. Cirius’s MSDC-0602K improves non-invasive markers of liver health, glycemic control, and importantly, led to the reduction of chronically elevated fasting insulin levels. The company serves healthcare sectors specifically for patients suffering from liver and metabolic diseases. Cirius Therapeutics is headquartered in Kalamazoo, Michigan, the US.
For a complete picture of Azemiglitazone’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
